Tabla 2: Desenlaces primarios y eventos adversos adicionales.

Desenlace

Eventos (%), [pacientes]

p*

RR

(IC 95%)

Población

(N = 88)

Efedrina

(N = 43)

Norepinefrina

(N = 45)

Bradicardia

5 (0.67),

[4]

2 (0.57),

[2]

3 (0.77),

[2]

> 0.9999

1.40

(0.24-8.35)

Hipotensión

123 (16.4),

[55]

94 (25.9),

[40]

29 (7.5),

[15]

< 0.0001

0.29

(0.20-0.43)

Uso/cambio

de vasopresor

361 (31.6),

[88]

69 (12.3),

[43]

292 (49.9),

[45]

< 0.0001

4.04

(3.20-5.12)

Bradicardia

o hipotensión

127 (11.1),

[57]

95 (16.9),

[40]

32 (5.5),

[32]

< 0.0001

0.32

(0.22-0.47)

Bradicardia

o hipotensión o

uso de atropina

140 (12.2),

[65]

102 (18.2),

[43]

38 (6.5),

[22]

< 0.0001

0.36

(0.25-0.51)

Bradicardia

o hipotensión o

uso/cambio

de vasopresor

397 (34.7),

[88]

103 (18.4),

[43]

294 (50.3),

[45]

< 0.0001

2.73

(2.25-3.31)

Evento adverso, n (%)

Náusea

33 (37.5)

31 (68.9)

2 (4.6)

< 0.0001

0.07

(0.02-0.27)

Emesis

54 (61.4)

41 (91.1)

13 (30.2)

< 0.0001

0.33

(0.21-0.53)

* Prueba exacta de Fisher.

RR = riesgo relativo.

IC 95 = intervalo de confianza del 95%.